Navigation Links
EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health
Date:6/18/2009

VIENNA, Austria, and CUXHAVEN, Germany, June 18 /PRNewswire/ -- EUCODIS Bioscience, a company developing, manufacturing, and marketing enzymes and other proteins for the chemical industry, announced today that it has achieved an important milestone in the development of an undisclosed protein for Lohmann Animal Health (LAH), a leading provider of feed components and vaccines for farm animals. This achievement triggered a milestone payment from LAH to EUCODIS Bioscience.

EUCODIS Bioscience is developing an innovative protein that LAH plans to use as the active ingredient of a new product line. EUCODIS Bioscience and LAH currently have two development agreements in place. In February, EUCODIS Bioscience announced the achievement of a development milestone pertaining to a separate agreement with LAH.

"We have made significant progress in developing a protein showing innovative properties that will bring significant value for agricultural applications," said Rudy Pandjaitan, PhD, CEO of EUCODIS Bioscience. "We are excited about this project, as the product we are developing for our partner LAH has the potential to open a new market in the food and feed industry."

About EUCODIS Bioscience

EUCODIS Bioscience GmbH develops, manufactures, and markets industrial enzymes.

EUCODIS Bioscience' products help customers in the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties.

EUCODIS Bioscience originally focused on developing enzymes for industrial partners, including GlaxoSmithKline, Henkel, and Lohmann Animal Health. Since 2009, the Company also markets its own products.

Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Com
'/>"/>

SOURCE EUCODIS Bioscience
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015  CipherHealth, a leading provider of innovations and ... sent representatives to the Nepalese American Nursing Association to ... nurses to Nepal to aid ... month. In addition to helping fund the travel costs ... for much-needed medical supplies for the mission.  ...
(Date:5/5/2015)... 2015   InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" ... today that it will release its full financial results for ... 11 th before the open, followed by a conference ... and business outlook. Participants should call (888) 243-4451 ... and request the InspireMD call. A live webcast of the ...
(Date:5/5/2015)... 5, 2015  Trovagene, Inc. (NASDAQ:  TROV), a ... financial results for the three months ended March ... quarter, we presented favorable clinical results at ASCO ... demonstrating our Precision Cancer Monitoring platform,s ability to ... and lung cancers," said Antonius Schuh, Ph.D., chief ...
Breaking Medicine Technology:Five Nurses and Medical Supplies En Route to Nepal With Donation Assistance from CipherHealth 2InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th 2InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th 3Trovagene, Inc. Announces First Quarter 2015 Financial Results 2Trovagene, Inc. Announces First Quarter 2015 Financial Results 3Trovagene, Inc. Announces First Quarter 2015 Financial Results 4Trovagene, Inc. Announces First Quarter 2015 Financial Results 5Trovagene, Inc. Announces First Quarter 2015 Financial Results 6
... 15, 2011 The U.S. Food and Drug Administration approved ... patients undergoing magnetic resonance imaging (MRI) of the central ... Gadavist was approved by the FDA on March ... system, helping to detect and visualize lesions that disrupt ...
... and ALISO VIEJO, Calif., March 15, 2011 ... disease screening, cell/molecular biology and immunological testing for ... an agreement with Ambry Genetics, a global leader ... healthcare and life sciences industries, that will allow ...
Cached Medicine Technology:FDA Approves Gadavist for Central Nervous System Scans 2LABS, Inc. Announces Alliance with Ambry Genetics to Expand Testing Solutions for the Reproductive Health Industry 2
(Date:5/5/2015)... Atlanta, Georgia (PRWEB) May 05, 2015 ... Software of Victoria BC announced the Skedans Sensor ... The platform, for mobile and web app developers, provides ... from airborne and mobile sensors. , The Skedans Sensor ... at the intersection of the Internet of Things, Web ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 This year, ... Medals, four Special Merit Awards, three Gold Medals and ... projects are described as follows: , (1) Grand Prize ... Robotic Mannequin for Fashion Design and Fitting, Principal Investigator: ... , The apparel industry relies very much on the ...
(Date:5/5/2015)... New York, NY (PRWEB) May 05, 2015 ... Marketing Platform that enables businesses to deploy Mobile Engagement ... Constant Contact . ProTexting clients can now leverage ... Marketing reach by collecting and syncing subscribers’ e-mail addresses ... Kassabov says “We have recognized that the growing trend ...
(Date:5/5/2015)... 2015 Rare Genomics Institute ... study aimed at determining how crowdfunding can promote scientific ... international non-profit providing rare disease patients with access to ... scientists and researchers, and help for payment of these ... excited to see how crowdfunding will not only help ...
(Date:5/5/2015)... 2015 On April 8th, 2015, at ... Choices Recovery sponsored Durkin Entertainment’s “RockNRolla” EcoLuxe Lounge, a ... of sustainable product placement in TV and film. ... providers of ecologically sound and socially conscious products and ... event that makes appearances at various awards ceremonies and ...
Breaking Medicine News(10 mins):Health News:Skedans Systems Announces Skedans Sensor Collaboration Platform at AUVSI's Unmanned Systems 2015 in Atlanta 2Health News:PolyU wins top prizes in Geneva’s Invention Expo 2Health News:PolyU wins top prizes in Geneva’s Invention Expo 3Health News:PolyU wins top prizes in Geneva’s Invention Expo 4Health News:PolyU wins top prizes in Geneva’s Invention Expo 5Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 2Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 3Health News:Rare Genomics Institute to Study Impact of Crowdfunding on Rare Diseases 2Health News:Choices Recovery Mishawaka Talks About Overcoming Adversity with Actor Matthew Ziff at the “RockNRolla Movie Awards” EcoLuxe Lounge 2
... Focus is system that regulates blood pressure and fluid ... News) -- New research is shedding some light on ... cause miscarriage and death in pregnant women. , "Preeclampsia ... 10 percent of all pregnancies in the United States," ...
... (FA) is a rare and dangerous disease, new laboratory research ... shows it may lead researchers toward clues in more common ... a study published in the Sept. 11 issue of the ... proteins to DNA damage sites is controlled by replication in ...
... the biggest student drinking problems have so far failed to turn ... in the September issue of the Journal of Studies on ... students, alcohol habits showed little change over a dozen years. In ... two weeks; in 2005, 56 percent said the same. And although ...
... blind and visually impaired often rely on others to provide ... with this method is that it doesn,t give them the ... Lahav of Tel Aviv University,s School of Education and Porter ... to the blind, Dr. Lahav has invented a new software ...
... Administration,s (FDA) recent decision to approve the radioimmunotherapy (RIT) ... lymphoma (NHL). "This is welcome news for ... Ph.D., president of SNM and director of nuclear medicine ... "We,ve known for some time that RIT works extremely ...
... Television journalist Veronica ... and now directs her brother,s story to the White House , ... Los Angeles, CA (PRWeb) September 10, 2009 -- After ... brought the tale of her brother Eric,s tragic battle against health care red tape to ...
Cached Medicine News:Health News:Research Seeks Cause of Preeclampsia 2Health News:Replication at DNA damage sites highlights Fanconi anemia and breast cancer proteins 2Health News:Heavy-drinking colleges showing no improvements 2Health News:Virtual maps for the blind 2Health News:Virtual maps for the blind 3Health News:SNM applauds FDA's decision to approve Zevalin 2Health News:Television Journalist Veronica De La Cruz Brings Her Brother's Story from L.A. to White House in Fight for Health Care Reform 2Health News:Television Journalist Veronica De La Cruz Brings Her Brother's Story from L.A. to White House in Fight for Health Care Reform 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: